Skip to content

MDMA research published in 2019

Page 2 of 4: studies 21 to 40 of 71, newest first. Back to the MDMA overview

Studies

Differential role of dose and environment in initiating and intensifying neurotoxicity caused by MDMA in rats

BMC Pharmacology and Toxicology August 5, 2019 Ibrahim M. Shokry, Connor J. Shields, John J. Callanan et al.

Background MDMA causes serotonin (5-HT) syndrome immediately after administration and serotonergic injury in a few days or weeks. However, a serotonin syndrome is not always followed by serotonergic injury, indicating different mechanisms responsible for two adverse effects. The goal of present study was to determine causes for two adverse events and further test that dose and environment have...

DOI: 10.1186/s40360-019-0326-6 (opens in new tab) Full text (opens in new tab) MDMA Toxicity Serotonin syndrome Serotonergic injury Hypothermia +6

Culturally informed research design issues in a study for MDMA-assisted psychotherapy for posttraumatic stress disorder

Journal of Psychedelic Studies July 30, 2019 Monnica T. Williams, Sara Reed, Ritika Aggarwal 87 citations

Recent research suggests that psychedelic drugs can be powerful agents of change when utilized in conjunction with psychotherapy. Methylenedioxymethamphetamine (MDMA)-assisted psychotherapy has been studied as a means of helping people overcome posttraumatic stress disorder, believed to work by reducing fear of traumatic memories and increasing feelings of trust and compassion toward others,...

Intersectional insights from an MDMA-assisted psychotherapy training trial: An open letter to racial/ethnic and sexual/gender minorities

Journal of Psychedelic Studies July 24, 2019 Terence H. W. Ching

The road to the current psychedelic renaissance in research on ±3,4-methylenedioxymethamphetamine (MDMA) – the active ingredient of the drug Ecstasy – for addressing treatment-resistant post-traumatic stress disorder has been fraught with political and academic bias, as well as cultural stigma among underserved populations, all of which serve as barriers to minority inclusion and participation....

First study of safety and tolerability of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in patients with alcohol use disorder: preliminary data on the first four participants.

BMJ Case Reports July 15, 2019 Ben Sessa, Chloe Sakal, Steve O’Brien et al. 55 citations

We present the preliminary data in an ongoing open-label safety and tolerability proof of concept study exploring the potential role for 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in treating patients with alcohol use disorder. At this stage, seven participants have completed the full 8-week MDMA-assisted psychotherapy course, including two therapy sessions each with MDMA....

Risk intentions following pill test scenarios are predicted by MDMA use history and sensation seeking: A quantitative field study at an Australian music festival.

Drug and Alcohol Review July 2019 Ross C Hollett, Natalie Gately

Most Australian Governments have resisted supporting formal pill testing (drug checking) at music festivals. With limited knowledge available regarding post-pill test substance use behaviour, we aimed to understand risk behaviour within three pill test scenarios by determining the individual factors which predict subsequent risky or risk reduction intentions. Music festival attendees (N = 276)...

Concurrent Inhibition of Vesicular Monoamine Transporter 2 Does Not Protect Against 3,4-Methylenedioxymethamphetamine (Ecstasy) Induced Neurotoxicity.

Toxicological sciences : an official journal of the Society of Toxicology July 1, 2019 Aram B Cholanians, Andy V Phan, Serrine S. Lau et al.

3, 4-Methylenedioxymethamphetamine (MDMA) is a hallucinogenic amphetamine derivative. The acute effects of MDMA are hyperthermia, hyperactivity, and behavioral changes, followed by long-term serotonergic neurotoxicity in rats and primates. However, the underlying mechanisms of MDMA neurotoxicity remain elusive. We reported that pretreatment of rats with Ro 4-1284, a reversible inhibitor of the...

Cognitive Effects of MDMA in Laboratory Animals: A Systematic Review Focusing on Dose.

Pharmacological Reviews July 1, 2019 Madeline M. Pantoni, Stephan G Anagnostaras

±3,4-Methylenedioxymethamphetamine (MDMA) is a synthetic, psychoactive drug that is primarily used recreationally but also may have some therapeutic value. At low doses, MDMA produces feelings of relaxation, empathy, emotional closeness, and euphoria. Higher doses can produce unpleasant psychostimulant- and hallucinogen-like adverse effects and therefore are usually not taken intentionally....

DOI: 10.1124/pr.118.017087 (opens in new tab) Full text (opens in new tab) Animals, laboratory N-methyl-3,4-methylenedioxyamphetamine Cognition Dose-response relationship, drug

Incorporating MDMA as an Adjunct in Emotionally Focused Couples Therapy With Clients Impacted by Trauma or PTSD

The Family Journal July 1, 2019 Katie Almond, Robert Allan 7 citations

This article explores incorporating 3,4-methylenedioxymethamphetamine (MDMA) as an adjunct in emotionally focused couples therapy (EFT) with clients in which at least one participant has endured a traumatic experience and reports symptoms of post-traumatic stress disorder (PTSD). Despite classification as a Schedule I drug on the Controlled Substances Act (CSA), in 2017 the U.S. Food and Drug...

Psychedelic drugs—a new era in psychiatry?

Dialogues in Clinical Neuroscience June 30, 2019 David Nutt 131 citations

This article covers the renaissance of classical psychedelic drugs such as psilocybin and LSD plus 3,4-methylene dioxymethamphetamine (MDMA-ecstasy) in psychiatric research. These drugs were used quite extensively before they became prohibited. This ban had little impact on recreational use, but effectively stopped research and clinical treatments, which up to that point had looked very...

New psychoactive substances: psychiatrist's view

Interactive science June 21, 2019 Andrey Viktorovich Antsyborov, Irina Vladimirovna Dubatova 1 citation

Appearing not long ago, new psychoactive substances (designer drugs), including synthetic cannabinoids, derivatives of cathinone, phenethylamines, new stimulants, synthetic opioids, tryptamine derivatives, phencyclidine, piperazine, the GABA (A/B) receptors agonists, have become a serious problem for consumers and for physicians. Consumers of these substances are attracted primarily by the...

DOI: 10.21661/r-497066 (opens in new tab) Full text (opens in new tab) MDMA Synthetic cannabinoids Designer drug Cathinone +9

Drugs—without the hot air: minimising the harms of legal and illegal drugs

Practical Neurology June 13, 2019 Charis Wong 1 citation

In the wake of recent changes to legislation on cannabinoid prescribing we decided to discuss Drugs – without the hot air 1 (figure 1) for the latest Edinburgh Neurology Book Club. Written by David Nutt, Professor of Neuropsychopharmacology, this book provides his account of how he became the ‘scientist who was sacked’ by the UK Home Secretary, after comparing the risks of harm from...

DOI: 10.1136/practneurol-2019-002288 (opens in new tab) Ecstasy Cannabis Recreational drug Neuropsychopharmacology +2

Sensitization to the prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA).

Neuropharmacology June 2019 Daniel W Curry, Laís F. Berro, Andie R Belkoff et al.

The recreational drug 3,4-methylenedioxymethamphetamine (MDMA) has well documented prosocial effects and is currently under clinical investigation as a treatment for patients with PTSD, autism, and other conditions. Early clinical trials have found that MDMA-assisted therapy may have robust long-lasting therapeutic effects, yet the mechanism by which acute treatments produce these long-term...

DOI: 10.1016/j.neuropharm.2019.03.017 (opens in new tab) Full text (opens in new tab) MDMA 3,4-methylenedioxymethamphetamine 5-ht2a Sensitization +1

Dopamine and serotonin antagonists fail to alter the discriminative stimulus properties of ±methylenedioxymethamphetamine

Behavioural Pharmacology June 1, 2019 Susan Schenk, Quenten Highgate 2 citations

Most studies on discriminative stimulus effects of 3,4-methylenedioxymethamphetamine (MDMA) have been conducted using a relatively low dose (1.5 mg/kg), and those studies have invariably implicated serotonergic mechanisms. In contrast, dopaminergic mechanisms mediate the discriminative stimulus effects of amphetamine (AMPH). Some studies have suggested that the discriminative stimulus effects...

Metabolites of the ring-substituted stimulants MDMA, methylone and MDPV differentially affect human monoaminergic systems

Journal of Psychopharmacology April 30, 2019 Dino Luethi, Karolina E. Kolaczynska, Melanie Walter et al. 39 citations

Background: Amphetamine analogs with a 3,4-methylenedioxy ring-substitution are among the most popular illicit drugs of abuse, exerting stimulant and entactogenic effects. Enzymatic N-demethylation or opening of the 3,4-methylenedioxy ring via O-demethylenation gives rise to metabolites that may be pharmacologically active. Indeed, previous studies in rats show that specific metabolites of...

Variability in content and dissolution profiles of MDMA tablets collected in the UK between 2001 and 2018 – A potential risk to users?

Drug Testing and Analysis April 22, 2019 Lewis Couchman, Anca Frinculescu, Catarina Sobreira et al. 35 citations

Abstract 3,4‐Methylenedioxymethamphetamine (MDMA, Ecstasy) tablets are widely used recreationally, and not only vary in appearance, but also in MDMA content. Recently, the prevalence of high‐content tablets is of concern to public health authorities. To compare UK data with other countries, we evaluated MDMA content of 412 tablets collected from the UK, 2001–2018, and investigated within‐batch...

DOI: 10.1002/dta.2605 (opens in new tab) MDMA Ecstasy Dissolution Immediate release +1

Oxytocin receptor gene variations and socio-emotional effects of MDMA: A pooled analysis of controlled studies in healthy subjects.

PLoS One April 13, 2019 Patrick Vizeli, Matthias E. Liechti 37 citations

Methylenedioxymethamphetamine (MDMA) increases oxytocin, empathy, and prosociality. Oxytocin plays a critical role in emotion processing and social behavior and has been shown to mediate the prosocial effects of MDMA in animals. Genetic variants, such as single-nucleotide polymorphisms (SNPs), of the oxytocin receptor (OXTR) may influence the emotional and social effects of MDMA in humans. The...

Receptor-Enriched Analysis of functional connectivity by targets (REACT): A novel, multimodal analytical approach informed by PET to study the pharmacodynamic response of the brain under MDMA

Neuroimage April 4, 2019 Ottavia Dipasquale, Pierluigi Selvaggi, Mattia Veronese et al. 79 citations

One of the main limitations of pharmacological fMRI is its inability to provide a molecular insight into the main effect of compounds, leaving an open question about the relationship between drug effects and haemodynamic response. The aim of this study is to investigate the acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on functional connectivity (FC) using a novel multimodal method...

Oxytocin-dependent reopening of a social reward learning critical period with MDMA

Nature April 3, 2019 Romain Nardou, Eastman M. Lewis, Rebecca Rothhaas et al. 343 citations

A critical period is a developmental epoch during which the nervous system is expressly sensitive to specific environmental stimuli that are required for proper circuit organization and learning. Mechanistic characterization of critical periods has revealed an important role for exuberant brain plasticity during early development, and for constraints that are imposed on these mechanisms as the...

MDMA and Pavlovian Fear Memory: Dose‐Effect Analysis

The FASEB Journal April 1, 2019 Madeline M. Pantoni, Stephan G Anagnostaras

±3,4‐methylenedioxymethamphetamine (MDMA) is a recreational drug that is also being pursued as a therapeutic for PTSD and other mood and anxiety disorders. Despite strong evidence of its therapeutic potential, these pursuits are hindered by evidence that MDMA produces robust neurotoxicity and cognitive deficits at high doses. These findings, however, may not generalize to typical recreational...

A Review of 3,4-methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy

Frontiers in Psychiatry March 20, 2019 Ben Sessa, David Nutt, Laurie Higbed 141 citations

This paper provides a brief review of the history, proposed pharmacological mechanisms, safety issues, and clinical applications of the medicine 3,4-methylenedioxymethamphetamine (MDMA). Most clinical MDMA research in patients to date has focused on MDMA-assisted psychotherapy to treat posttraumatic stress disorder (PTSD). In this review paper other potential therapeutic applications for MDMA...